US Pharma MarketingAbbVie claims Phase 3 win of multiple myeloma drug, seeking to enter crowded market
AbbVie says etentamig cut myeloma progression risk 60% in a Phase 3 trial, setting up a safety-focused pitch against Tecvayli, Elrexfio and Lynozyfic. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…
AbbVie said its T cell engager etentamig cut the risk of disease progression or death by 60% compared with standard therapies in a Phase 3 multiple myeloma trial. The Chicago-area company is now planning to ...
Source: Endpoints News